Summary We have defined a novel ovarian cancer-associated membrane antigen, 14C1, using human monoclonal antibodies derived by EBV-transformation of in situ sensitised patients' B-cells. The pattern of recognition of this antigen by these antibodies suggests that at least three epitopes are discernable. These antibodies can be used to promote the in vitro killing of ovarian cancer cells by activated macrophages and cytokines, implying a role for this antigen in the immunotherapy of ovarian malignancies. Evidence is presented that the 14C1 antigen may have some transmembrane signalling function.
Ovarian cancer continues to kill significant numbers of women every year. The recent development of aggressive, platinum-based chemotherapeutic protocols has delayed the onset of post-surgical recurrence, but the overall survival is still poor (Slevin, 1986) .
Recent years have seen the description and development of several mouse monoclonal antibodies as potential diagnostic agents and/or therapeutic tools in the monitoring and treatment of ovarian cancer. One in particular, CA-125, is used extensively in the routine post-surgical monitoring of these patients (Sekine et al., 1985) and another, HMFG-2, has been used for the treatment and imaging of intra-peritoneal residual disease following surgery (Ward et al., 1988) . In addition, a number of other antibodies have been described which usually (Sakakibara et al., 1988) , but not always (Mattes et al., 1987) , define high molecular weight mucinous or carbohydrate antigens.
In several cases, murine antibodies such as HMFG2 have shown good clinical potential in ovarian cancer, particularly for the treatment of recurrent ascites rather than solid metastatic nodules (Ward & Wallace, 1987) . However, murine antibodies are known to solicit an 'anti-mouse' response from the human immune system (Pimm et al., 1985; Reynolds et al., 1986 ) and this could seriously diminish their clinical usefulness. Although such materials can be 'humanised', the most satisfactory procedure would be to use a wholly human antibody, provided one of the correct specificity could be found.
Additionally, although antibodies raised in mice are undoubtedly of great clinical use, they describe moieties which are antigenic in mice and so may not reflect the antigenicity of a particular tumour type in the human host. Working from the premise that antibody bound to tumour in situ will be specifically directed against that tumour, the production of human, anti-cancer antibodies from Epstein-Barr virustransformed human lymphocytes has been investigated. A small number of such antibodies has been reported, particularly for melanoma and breast or colonic tumours (Haspel et al., 1985; Kan-Mitchell et al., 1986; Kjeldsen et al., 1988) .
In a previous study (Gallagher et al., 1991a) , we described the partial characterisation of an antigen, '14C1', defined with a human antibody produced by EBV-transformation of the lymph-node cells of ovarian cancer patients (Al-Azzawi et al., 1987) , and demonstrated its membrane expression. The expression of 14C1 was highly restricted to ovarian epithelial tumours, particularly of the clear-cell carcinoma and serous or mucinous cystadenocarcinoma types, of which 88% were positive. A wide range of other normal and malignant tissue did not express the 14C1 antigen. We consider this antigen to be particularly important because it has been defined by a human antibody derived from the B-cells in an involved lymph-node; strongly suggesting that this antigen was the object of an anti-tumour immunological response at the time of resection. Such an antigen may represent a potent target for both active and passive immunotherapy in the postsurgical treatment of ovarian cancer. For this reason, we examined a range of anti-14C1 antibodies and investigated their utility as tools for marking the antigen, with particular reference to directing cellular effectors against the tumour.
We describe here the definition of three epitopes on the 14C1 antigen and the use of one particular antibody to kill ovarian cancer cells in vitro by monocyte-mediated ADCC. We further report the observation that the 14CI antigen may have some transmembrane signalling function.
Materials and methods
Preparation of the anti-14C1 secreting cell-lines The anti-14CI secreting cell-lines were prepared and selected as previously described (Al-Azzawi et al., 1987; Gallagher et al., 1991a Blots were 'blocked' by incubating in complete medium for 1 h at room temperature, then stained with 400 ng ml-' of the appropriate anti-14C1 antibody in complete medium for a further 90 min. Following thorough washing in PBS containing 0.05% (v/v) Tween-20 (PBS-Tween; Sigma), alkaline-phosphatase conjugated, goat anti-human IgG ('y-chain specific; Sigma) was diluted 1:1000 in PBS-Tween and added for 1 h at room temperature, after which time the blot was again extensively washed. The washed blots were equilibrated in substrate buffer (100 mM tris, 25 mM diethanolamine, 100 mM NaCl, 2 mM MgC12; pH 9.55) and the bands visualised by exposure to a substrate solution comprising 0.33 mg ml-' nitrobluetetrazolium in substrate buffer, to each ml of which was added 6.7 ILl of 2 mg ml-' phenazine methosulphate in water and 3.4 LI of 40 mg m'l 5-bromo-4-chlo-3-indolyl phosphate (p-toluidine salt) in dimethylformamide (all reagents from Sigma), according to the method of Ey and Ashman (1976) . Under these conditions, the conjugate detects not only the test antibody (if bound) but also IgG heavy chain already present in the sample, which therefore appears in all the tracks at around 48 kD; in some cases, heavier bands at 80-120 kD are also detected by this conjugate in membrane preparations. The conjugate does not detect either kappa or lambda light chain nor any other material lighter than heavy chain.
Cell-ELISA
In order to investigate the binding of the various antibodies to the OWmM1 cell-line, a 'Cell-ELISA' was carried out, as previously described (Al-Azzawi et al., 1987) .
In vitro cytotoxicity assay
The ovarian cancer cell-line OWmM1 was used as the target cell in all cases; we have previously shown this line to have characteristics associated with primary human ovarian tumours (Al-Azzawi et al., 1987; Gallagher et al., 1989) .
The cytotoxicity assay used was developed from that of Johnson and Adams (1986) , where target cell DNA was labelled with 3H-thymidine. Monocytes were isolated from the peripheral blood of healthy adult volunteers in a single step by centrifugation over the density separation medium 'Monodenz' (Nycomed). Monocytes were activated by a 24 h exposure to supernatant (diluted 1:1 with complete medium) from 4-day mixed lymphocyte cultures (MLC; human), from which the immunoglobulin had been removed by passage over Protein-A Sepharose (Pharmacia-LKB); MLC were carried out in complement-depleted foetal calf serum. Activated monocytes were washed (x 3) prior to use. MLC supernatants prepared in this way contain a number of cytokines known to activate monocytes to cytotoxicity, including yinterferon, interleukin-4, interleukin-2 and granulocyte/macrophage colony stimulating factor (Nathan et al., 1984; Crawford et al., 1987; Malkovsky et al., 1987; Grabstein et al., 1986; Cannistra et al., 1987) .
Target cells were seeded to semi-confluence in 96-well plates (Costar) in 100 IlI complete medium, containing 10 lsCi ml-' 3H-thymidine (TRK 328; Amersham) and allowed to grow for 24 h. After this time, the cells were virtually confluent, totally adherent and would generally have incorporated 30,000-60,000 c.p.m. per well. The radiolabelled culture fluid was removed and the cells subjected to four rounds of medium exchange (200 lI), with a 10 min period between to allow diffusion of unbound label from the cell. Subsequent spontaneous release of label from the cells was found to be less than 5%. Anti-14CI antibody (14ClI.) was added at various concentrations (see Results) and incubated for 1 h after which it was removed, the cells washed twice by medium exchange and the activated monocytes added (E:T = 10: 1): killing was allowed to proceed for 24 h. After this period, both monocytes and dead target cells were removed by repeated gentle washing and the remaining (live) cells lysed with 150 fsl of a 1% (w/v) solution of sodium dodecyl sulphate (Sigma) in distilled water. The radioactivity contained in 100ly1 of this lysate (and hence percentage live cells remaining; PLCR) was determined and taken as a simple fraction of the total radioactivity incorporated (target cells labelled and thereafter untreated, then lysed). The 'Percentage Killing' was calculated as 'PK = 100 -PLCR'. Controls (see Table I ) included: 14ClI. alone; 14ClI. + resting monocytes; resting or activated monocytes alone, or in combination with 1 ltg ml-' human myeloma IgG (as irrelevant antibody). In no case was significant killing observed unless activated monocytes were present. Higher degrees of killing were dependent upon the presence of activated monocytes and related to the amount of 14Cl. antibody present (see Figure 3 ).
Results
Western blotting with different anti-14CJ antibodies suggests the presence of discrete epitopes on the 14C1 antigen We have previously described how the 14C1 antigen appears as a single band on primary ovarian malignant tissue (Gallagher et al., 1991a) . Using the five antibodies now available, we extended the study to include samples of serous cystadenocarcinoma, mucinous cystadenocarcinoma and clearcell carcinoma of the ovary and we investigated whether all the antibodies described the same distribution pattern or whether this would vary with the antibody. The results are shown in Figure la (Figure le) . In each case, the same antibodies were used for blotting; track A: al4Cl.l; track B: al4Cl.2; track C: al4CI.3; track D: al4Cl.4; track E: al4Cl.5.
In the case of all five tissue specimens, a heavy band appears around the 48 kD mark, which is known to be due to the direct detection of IgG heavy chain from IgG contaminating the sample. The faint bands present at higher molecular weights in all five samples are not defined, but have been disregarded from our analysis since they are common to all tissues tested here and are visualised by the conjugate alone (not shown) and are therefore not related to the tumour type.
The bands below the 48 kD region are held to be specifically detected on ovarian cancer specimens (Gallagher et al., 1991a) . In some cases a single band is detected (for example, track A, Figure lc ) and in others a double band is observed (track A, Figure ld) , at or around the 25 kD mark. A 32 kDa antigen is also detected by all antibodies on all tumours, except for the case of antibody al4Cl1.3 and the mucinous tumour. A clear difference in the bands recognised by the different antibodies is shown, suggesting that the antibodies are recognising different epitopes on the peptide chains which make up the 14C1 antigen. After consideration of the pattern of antibody binding, we believe that three epitopes are being detected over the three tumour types.
Relative binding of the anti-14C1 antibodies to the 14C1 antigen In order to gain some insight into the use of these antibodies as targeting agents in models of ovarian cancer based round the OWmM1 cell line, we investigated their relative ability to bind to this cell line, in a cell-ELISA. All five antibodies were tested and found to give similar, but distinct levels of binding.
The binding curves for the antibodies which exhibited the highest (al4Cl.l) and the lowest (al4Cl.2) binding are shown in Figure 2 ; it can be seen that there is a 10-fold difference in binding between these two antibodies and xl4Cl .1 was therefore used in further studies (below). This difference will reflect a combination of epitope density and binding affinity and is probably applicable only to this cellline under our assay conditions; we fully expect that the relationship between these antibodies will be different on primary samples and this is an area of current investigation. Given the utility of the OWmMl line is an in vitro and in vivo model of human ovarian cancer however (Gallagher et al., in submission 1991b) , we feel that it is relevant to draw attention to differences in antibody binding to these cells. Activated monocytes can utilise the alJ4CL.I antibodies for ADCC-mediated killing of 0 WmMJ
As part of a programme to investigate the use of the 14C1 antigen as a possible target structure for immunotherapy of ovarian cancer, we attempted to kill these cells with the al4Cl.l antibody and activated peripheral blood monocytes as ADCC effectors. OWmM 1 cells were labelled as described and exposed to activated effector cells in the presence of increasing amounts of antibody. As shown in Table I , killing was wholly dependent upon the presence of specific antibody together with activated effector cells. That the antibody was acting to form a 'bridge' between the effector and target cells is indicated in Figure 3 observed to occur, beginning at levels of antibody previously shown to give significant binding to the target cells ( Figure  2 ). ADCC reached 68%, while activated effectors alone usually caused 15-20% lysis. aAntibodies were added at 250 ng IgG per ml. "The effector to target cell ratio was 10: 1. c The mean ± std.dev. of five observations is shown. The ovarian cancer cell-line OWmM was radiolabelled, pre-coated with a range of concentrations of the anti-14Cl antibody 14Cl1.1 and exposed to activated monocytes at an effector-to-target cell ratio of 10:1, as described in the text. Significant killing was observed, which was seen to be dependent upon the concentration of antibody used. For controls, see Table I . Results are expressed as the mean ± std.dev. of at least five observations. Synergy between the al4CL.J antibody and TNF-L in the killing of O WmMI It has been suggested that monocyte-mediated killing is carried out largely by tumour-necrosis factor (TNF-a; (Feinmann et al., 1987) ) associated with the cell membrane (Decker, Lohmann-Mattes & Gifford, 1987 The reasons as to why the 14C1 antigen appears at both 26 and 32 kDa (with either single or double banding at each weight) are unclear at present, but they may indicate that the 14C1 molecule is subject to proteolytic cleavage at or close to the outer surface of the membrane, as has been documented for a variety of growth factor receptors, such as CD23 and CD25, or it may result from the processing procedure 'fixing' partly processed forms of the molecule (as has been described for the EGF receptor; Gill et al., 1987) . Alternatively, these bands may represent different glycoforms of the antigen. Studies to formally address these questions are underway.
In addition, it appears that several epitopes are being 10 100 conc. TNF (ng ml-') (Neale et al., 1990) ), the apparent cooperation in killing between al4C1 and TNFa leads us to favour the growthfactor receptor model which would predict that the 14C1 molecule is subject to cleavage at or close to the membrane, resulting in the two molecular weight forms being identified from tissue. We are attempting to develop possible therapeutic applications directed against the 14C1 antigen. One of the most appealing is to use the antibodies in the context of intraperitoneal ADCC. The contained environment within which ovarian cancers are found enhances the potential utility of this approach; macrophages are obvious effectors since it has been shown that they are capable of killing tumour cells by this method and are prevalent within the peritoneal cavity (Adams et al., 1984; Johnson & Adams, 1986; Lubeck et al., 1988) . In addition, activated macrophages adoptively transferred into the human peritoneal cavity remain there for several days (Stevenson et al., 1987) . The results described in this report clearly illustrate that the 14C1.1 antibody is capable of allowing cytokine-activated peripheral blood monocytes to kill ovarian cancer cells in vitro, by an ADCC mechanism ( Figure 2 ) and so suggest a therapeutic potential for this reagent. It has been suggested that this form of killing is largely mediated by TNF-a (Zeigler-Heitbrock et al., 1986) , particularly membrane-associated TNF (Decker et al., 1987) . The results shown in Figure 4 show that the OWmM1 cell-line is sensitive to TNF and so the observed ADCC may be due to release of this factor. It was unexpected to note that this sensitivity to TNF was dependent upon the presence of the antibody and we can only conclude that antibody binding to the 14C1 molecule renders the cell TNF-sensitive, perhaps by some mechanism which initiates synthesis of the TNF receptor; thus it is possible that 14C1 has some transmembrane signalling function.
Cytokines have been used successfully in the treatment of experimental models of human ovarian cancer (Balkwill et al., 1987) , particularly those protocols which centre round TNF. Similarly, murine antibodies have been found to be of benefit, particularly for the treatment of recurrent ascites rather than solid metastatic nodules (Ward & Wallace, 1987) . The results presented in this report strongly suggest that the therapeutic efficacy of such agents would be greatly enhanced if used together.
In conclusion, we believe that the antibodies described here may be of clinical use in ovarian cancer. The further analysis of such anti-tumour responses involving 14C1 may provide tools with which the immune system can be manipulated as part of the post-surgical management of ovarian cancer.
